Trade Summary

4 days ago, Piekos Brian, serving as CFO at Kalvista Pharmaceuticals, Inc. (KALV), sold 1,767 shares at $15.57 per share, for a total transaction value of $27,507.00. Following this transaction, Piekos Brian now holds 13,762 shares of KALV.

This sale represents a 11.00% decrease in Piekos Brian's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, February 23, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, February 24, 2026, 1 day after the trade was made.

Kalvista Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.